Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Merkel Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 4Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × avelumab × Clear all
NCT03750071 2022-10-20

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Vaximm GmbH

Phase 1/2 Unknown
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡